Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma-Reference-Cited by-同舟云学术

Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma

Published:2014-08 Issue:8 Volume:24 Page:1223-1231
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Yavuz Sahzene¹,Apolo Andrea B.²,Kummar Shivaani²,del Rivero Jaydira³,Madan Ravi A.²,Shawker Thomas⁴,Reynolds James⁴,Celi Francesco S.¹⁵

Affiliation:

1. National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes, Endocrine, and Obesity Branch, National Institutes of Health, Bethesda, Maryland.

2. National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

3. National Institutes of Child Health Development, National Institutes of Health, Bethesda, Maryland.

4. Clinical Center, National Institutes of Health, Bethesda, Maryland.

5. Division of Endocrinology and Metabolism, Virginia Commonwealth University, Richmond, Virginia.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2013.0621

Reference39 articles.

1. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

2. Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs

3. Inappropriate Elevation of Serum Thyrotropin Levels in Patients Treated with Axitinib

4. Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

5. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab and Cabozantinib Immunotherapy Induced Thyroid Dysfunction Detected on 18F-FDG PET/CT in Renal Cell Carcinoma;Clinical Nuclear Medicine;2024-10

2. La tiroide sull’altalena degli inibitori delle tirosin-chinasi (TKI);L'Endocrinologo;2023-11-03

3. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors;Annales d'Endocrinologie;2023-05

4. Cabozantinib-Induced Severe Cardiac Dysfunction: A Case Report and a Systematic Review of the Literature;Cureus;2022-04-01

5. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review;Cancer Treatment Reviews;2022-02